title: Determination of skin concentrations of enrofloxacin in dogs with pyoderma.
abstract: OBJECTIVE
  To compare serum and skin concentrations of enrofloxacin in dogs with pyoderma with those of clinically normal dogs and to evaluate concentrations in dogs with superficial versus deep pyoderma.
  
  
  METHODS
  16 clinically normal dogs and 16 dogs with pyoderma.
  
  
  METHODS
  Enrofloxacin (approx 5 mg/kg of body weight, PO) was administered daily to all dogs. Serum samples and skin biopsy specimens were obtained on day 1 at 3 hours after drug administration and on day 3 immediately before and 3 hours after drug administration. Samples and specimens were assayed by high-performance liquid chromatography. Morphometric analysis was performed on skin biopsy specimens to determine correlation between inflammatory cells and peak tissue enrofloxacin concentration on day 1.
  
  
  RESULTS
  Morphometric analysis revealed high correlation between dermal inflammatory cell count and drug concentration in dogs with pyoderma.
  
  
  CONCLUSIONS
  At mean dosage of 5 mg/kg once daily, enrofloxacin tissue concentrations were significantly greater in dogs with pyoderma at 3 hours after pill administration. Enrofloxacin tissue concentration on day 3 at 3 hours after pill administration was 12.4 times the 90% minimum inhibitory concentration of enrofloxacin for Staphylococcus intermedius.
  
  
  CONCLUSIONS
  In dogs with pyoderma, therapeutic tissue concentrations of enrofloxacin are reached as early as 3 hours after drug administration.
authors.affiliation: Department of Medicine & Epidemiology, School of Veterinary Medicine, University of California, Davis 95616, USA.
authors.forename: T C
authors.initials: TC
authors.lastname: DeManuelle
authors.forename: P J
authors.initials: PJ
authors.lastname: Ihrke
authors.forename: C M
authors.initials: CM
authors.lastname: Brandt
authors.forename: P H
authors.initials: PH
authors.lastname: Kass
authors.forename: P R
authors.initials: PR
authors.lastname: Vulliet
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D001706:Biopsy; D004283:Dog Diseases / Q000188:drug therapy* / Q000378:metabolism; D004285:Dogs; D000077422:Enrofloxacin; D024841:Fluoroquinolones; D007249:Inflammation; D008826:Microbial Sensitivity Tests; D011711:Pyoderma / Q000188:drug therapy / Q000378:metabolism / Q000662:veterinary*; D015363:Quinolones / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D012867:Skin / Q000378:metabolism* / Q000473:pathology; D013210:Staphylococcus / Q000187:drug effects
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin